Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
Burning Rock Localizes as Investors Grow Impatient
Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…
Following Rough Year, Is Burning Rock Set to Turn the Corner?
Cancer testing specialist expects sharply slower growth this year than previous guidance due to Covid-related travel restrictions Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due…
